Journal profile · Medicine-Dermatology
Medicina Cutanea Ibero-Latino-Americana
ISSN 0210-5187 · eISSN 1989-8932 · Elsevier
Medicina Cutanea Ibero-Latino-Americana: diamond open access (no APC); no APC; median 118 days to acceptance (66 articles, last 24 months); 57 articles in 2025; indexed in Scopus.
Scope
Aims, scope and focus
Medicina Cutanea Ibero-Latino-Americana is published by Elsevier. By OpenAlex counts of its recent articles, its largest topics are Dermatology and Skin Diseases, Medicine and Dermatology Studies History and Cancer and Skin Lesions, together about 30.5% of its articles. Its main subfields are Dermatology. (generated from OpenAlex topic counts and CAS ranking data)
Medicina Cutánea Ibero-Latino-Americana es la revista oficial del Colegio Ibero-Latinoamericano de Dermatología y constituye un foro científico para dermatólogos e investigadores de Iberoamérica y otros países. Es una publicación cuatrimestral, de acceso abierto, que tras un proceso de revisión por pares doble ciego por parte de su comité editorial, publica artículos originales, revisiones y casos clínicos en español e inglés. Su alcance abarca los aspectos básicos, epidemiológicos, quirúrgicos y clínicos de la dermatología, con especial énfasis en las patologías prevalentes en poblaciones ibero-latinoamericanas y en los avances relevantes para la práctica dermatológica en la región.
From the journal's Aims & Scope
Research area (LetPub): Medicine-Dermatology
Editorial board by country: none in mainland China; most named Portugal 3, Chile 2, Argentina 1, Colombia 1 (7 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Dermatology and Skin DiseasesMedicine11.9%
- Medicine and Dermatology Studies HistoryMedicine9.6%
- Cancer and Skin LesionsMedicine9%
- Skin Diseases and DiabetesMedicine5.4%
- Genetic and rare skin diseases.Biochemistry, Genetics and Molecular Biology5.2%
- Cutaneous Melanoma Detection and ManagementMedicine5.1%
- melanin and skin pigmentationBiochemistry, Genetics and Molecular Biology4.9%
- Nonmelanoma Skin Cancer StudiesMedicine4.6%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Not covered
Not covered by this edition.
CAS Xinrui Journal Ranking (March 2026)Not covered
Not covered by this edition.
CAS Journal Ranking, previous upgraded edition (December 2023)Not covered
Not covered by this edition.
CiteScore quartiles (Scopus, June 2026 release)
| Subject | Quartile | Rank | Percentile |
|---|---|---|---|
| Dermatology | Q4 | 123/133 | 7th |
Scopus ranks journals by CiteScore within each subject: the 75th percentile and above is Q1, then a quartile every 25 points. A different system from the CAS zones.LetPub
Database indexing
ScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
MIAR, Latindex (Catálogo 2.0), BIBLATPublisher website
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- CiteScore 2026-06
- 0.2LetPub ·
- SJR 2026-06
- 0.11LetPub ·
- SNIP 2026-06
- 0.11LetPub ·
- h-index
- 9OpenAlex ·
- i10-index
- 8OpenAlex ·
- 2-year mean citedness
- 0.01OpenAlex ·
- Share of gold OA articles
- 0%LetPub ·
Articles by year OpenAlex count · 1,292 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 29 | 29 | 1 |
| 2025 | 57 | 57 | 10 |
| 2024 | 36 | 36 | 23 |
| 2023 | 24 | 24 | 27 |
| 2022 | 29 | 29 | 29 |
| 2021 | 61 | 61 | 34 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
118 daysMedian, submission to acceptance · P25–P75 64 days – 197 days
- Acceptance to online
- median 168 days (66 articles)
- Submission to online
- median 326 days
- Sample
- 66 articles with submission and acceptance dates (106 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Submission to publication (journal-reported)
- about 16 weeksDOAJ ·
- Peer review
- Double anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Diamond open access (no APC)DOAJ
Every article is open access and authors pay no article processing charge.
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | No APC | No | CC BY-NC-ND |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Article types accepted11
- artículo de revisión• Artículo de revisiónLength not stated
- artículo original• Artículo originalLength not stated
- artículos originalespublica artículos originales, revisiones y casos clínicos en español e inglésLength not stated
- caso clínico• Caso clínicoLength not stated
- caso para diagnóstico (imagen en dermatología)• Caso para diagnóstico (imagen en dermatología)Length not stated
- casos clínicospublica artículos originales, revisiones y casos clínicos en español e inglésLength not stated
- clinical caseClinical caseLength not stated
- editorial• EditorialLength not stated
- original articlesOriginal articlesLength not stated
- review articlesReview articlesLength not stated
- revisionespublica artículos originales, revisiones y casos clínicos en español e inglésLength not stated
Policy excerpts from the journal's websiteOpen access, Peer review
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Elsevier
- ISSN
- 0210-5187
- Electronic ISSN
- 1989-8932
- Society / sponsor
- Colegio Ibero-Latinoamericano de Dermatología
- Official links
FAQ
Frequently asked questions about Medicina Cutanea Ibero-Latino-Americana
How long does peer review take at Medicina Cutanea Ibero-Latino-Americana?
Based on the dates recorded on 66 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 118 days (interquartile range 64–197 days). Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Where are the editorial board members of Medicina Cutanea Ibero-Latino-Americana based?
Of the 7 board members whose country the journal's board page names, none are in mainland China; the countries named most often are Portugal (3), Chile (2) and Argentina (1). Counted from the institutions listed on the board page; for reference only.
Which databases index Medicina Cutanea Ibero-Latino-Americana?
According to LetPub and DOAJ records, Medicina Cutanea Ibero-Latino-Americana is indexed in Scopus and DOAJ.
Is Medicina Cutanea Ibero-Latino-Americana open access, and what is the APC?
Medicina Cutanea Ibero-Latino-Americana is a diamond open-access journal (no APC). It charges no article processing charge.
Sources and updates
The facts on this page come from LetPub, OpenAlex, DOAJ, Publisher website; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .